NetworkNewsBreaks – Predictive Oncology Inc.’s
Post# of 281
(Total Views: 214)
Posted On: 03/02/2020 2:31:23 PM
NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Proposed Acquisition Further Positions it to Aid Efforts to Accelerate Discovery of New Anti-Cancers, Anti-Virals and Vaccines
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today provided an update on its proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine. According to the update, this move further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines. The acquisition will provide POAI with QM’s exclusively licensed, proven machine learning framework (“CoRE”), developed at CMU. CoRE, a predictive model-building platform for drug screening and optimization campaigns, uses hybrid machine learning approaches to rapidly build predictive models to drive wet lab experimentation. The CoRE approach united with POAI-Helomics division’s PDx tumor profiling platform and tumor data database allows for a one-of-a-kind, end-to-end “discovery machine” to cost-effectively and rapidly generate potential therapeutic candidates, which can be fast-tracked with demonstrated activity in preclinical laboratory tests. In projects with pharmaceutical companies, QM demonstrated that the CoRE platform could reduce time by 50% in the discovery of novel therapeutics. This “speed-to-patient” is important not only in cancer and other diseases but vital when searching for treatments or vaccines for a novel virus such as the coronavirus 2019-nCoV.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today provided an update on its proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine. According to the update, this move further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines. The acquisition will provide POAI with QM’s exclusively licensed, proven machine learning framework (“CoRE”), developed at CMU. CoRE, a predictive model-building platform for drug screening and optimization campaigns, uses hybrid machine learning approaches to rapidly build predictive models to drive wet lab experimentation. The CoRE approach united with POAI-Helomics division’s PDx tumor profiling platform and tumor data database allows for a one-of-a-kind, end-to-end “discovery machine” to cost-effectively and rapidly generate potential therapeutic candidates, which can be fast-tracked with demonstrated activity in preclinical laboratory tests. In projects with pharmaceutical companies, QM demonstrated that the CoRE platform could reduce time by 50% in the discovery of novel therapeutics. This “speed-to-patient” is important not only in cancer and other diseases but vital when searching for treatments or vaccines for a novel virus such as the coronavirus 2019-nCoV.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)